Wound Care Biologics Market Size, Share, and Trends 2024 to 2033

Wound Care Biologics Market Size and Manufacturers

The global wound care biologics market size was estimated at USD 23.33 billion in 2023 and is predicted to hit around USD 41.94 billion by 2033 with a CAGR of 6.04% from 2024 to 2033.

Key Takeaways

• North America stood as a dominating region in 2023.
• Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
• By wound type, the chronic wound segment held the largest share of the market in 2023.
• By product, the biological skin substitutes segment dominated the wound care biologics market in 2023.
• By end user, the hospitals and clinics segment is observed to sustain the dominance during the forecast period.

Wound Care Biologics Market Overview

The wound care biologics market revolves around the offering of a class of advanced therapeutic products used in the treatment of wounds and tissue injuries. These biologics are derived from living organisms or their products and are designed to enhance the natural healing processes of the body. They differ from traditional wound care products by leveraging biological components to promote tissue regeneration, reduce inflammation, and accelerate the overall healing response.

Growth Factors

• The rising prevalence of chronic wounds, such as diabetic foot ulcers and venous leg ulcers, is a significant driver for the wound care biologics market. Biologics have shown promise in treating complex wounds that are challenging to heal through traditional methods.
• The global ageing population contributes to an increased demand for advanced wound care solutions. Older individuals often experience slower wound healing, making biologics an attractive option to expedite the healing process.
• Ongoing advancements in biotechnology and regenerative medicine contribute to the development of more effective wound care biologics. Improved formulations and delivery methods enhance the therapeutic potential of these products. Such advancements promote the wound care biologics market’s expansion.
• The increasing prevalence of diabetes worldwide contributes to a higher incidence of diabetic wounds. Wound care biologics, with their regenerative properties, can play a crucial role in managing and treating diabetic ulcers.

Wound Care Biologics Market Scope

Wound Care Biologics Market Dynamics

Driver: Growing prevalence of ulcers and chronic wounds

One of the main drivers of the wound care biologics market is the rising incidence of chronic wounds and ulcers, which is being driven by vascular disorders, diabetes, and ageing populations. There is an increasing need for enhanced treatment options as the cost of treating chronic wounds in healthcare throughout the world grows.

Growth factors, extracellular matrices, and stem cell-based therapies are examples of wound care biologics that provide potential new ways to treat complicated chronic wounds that frequently do not respond to standard medical therapy. They can also hasten the healing process. These cutting-edge biologics are vital to the therapy of chronic wounds because they stimulate tissue regeneration and lower inflammation.

Extracellular matrices improve wound closure by acting as a scaffold for tissue regeneration and cell migration. The promotion of tissue regeneration and immune response modulation are two ways that stem cell treatments contribute. Because these biologics are individualized, individuals with varying wound characteristics can get customized therapies that maximize their results. Further advancements in wound care biologics research and development might lead to revolutionary changes in the field of healthcare, particularly in the area of chronic wound treatment.

Restraint: High cost and regulatory challenge

Wound care biologics can be expensive compared to traditional wound care products. The high cost of production, research, and development, as well as the complexity of biological manufacturing processes, contribute to elevated pricing. This cost may limit access for certain patient populations and healthcare systems.

Additionally, regulatory approval for biologics can be a lengthy and complex process. Stringent regulatory requirements, especially for novel biologic products, can slow down market entry and increase development costs. Obtaining approval from regulatory authorities such as the FDA (U.S. Food and Drug Administration) or the EMA (European Medicines Agency) is crucial but can be a challenging and time-consuming process. Thus, this is expected to hamper the wound care biologics market over the forecast period.

Opportunity: Biotechnology and regenerative medicine

Considerable advancements in regenerative medicine and biotechnology are observed to offer lucrative opportunities for the wound care biologics market. Advances in tissue engineering, biomaterials, and cellular processes have resulted in the creation of biological medicines that possess improved healing properties. The industry's dedication to offering more efficient and individualized treatment choices for complicated wounds is demonstrated by the incorporation of cutting-edge technology, such as gene therapy and tissue regeneration, into wound care biologics.

Furthermore, the combination of biotechnology and artificial intelligence has made it easier to identify new therapeutic targets, which in turn has made it possible to create biologics that are customized to the unique profiles of individual patients. The potential of gene therapy to alter cellular processes genetically suggests that it may be useful in treating the underlying causes of chronic wounds. Precise treatments are made possible by tissue regeneration procedures that are guided by sophisticated imaging and diagnostic instruments.

The fields of wound care are changing as a result of the convergence of biologics and technology. In addition to enhancing the effectiveness of already available therapies, this combination creates opportunities for novel approaches that might completely alter the landscape of wound care in the future.

Wound Type Insights

The chronic wound segment held the dominating share of the wound care biologics market in 2023. The increasing prevalence of chronic wounds, particularly associated with ageing populations and the rise in conditions like diabetes, contributes to the demand for effective wound care solutions. Wound care biologics offer advanced treatment options for non-healing or slow-healing chronic wounds. For instance, according to the data by Mission Regional Medical Center, 6.7 million individuals are estimated to be living with chronic wounds at the moment, and over the next ten years, that figure is predicted to increase at a rate of more than two percent.

An ageing population, increased rates of illnesses and ailments including diabetes, obesity, and the aftereffects of radiation therapy are the main causes of the rising occurrence. Chronic wounds left untreated can result in a reduced quality of life and even limb amputation. Over $50 billion is spent on chronic wounds by the healthcare system. In the United States (US), about two million individuals with diabetes (about 29 million people, or 9.5% of the population) get a diabetic foot ulcer or other non-healing sore each year.

The acute wound segment is expected to grow at a moderate rate in the wound care biologics market over the projected period. Wound care biologics are designed to promote and accelerate the natural healing process of the body. In the case of acute wounds, such as surgical incisions, traumatic injuries, or burns, biologics can be applied to enhance tissue repair and reduce the overall healing time.

Product Insights

The biological skin substitutes segment, in 2023, held the largest share of the wound care biologics market. Biological skin substitutes provide a three-dimensional scaffold that mimics the extracellular matrix of natural skin. This scaffold offers structural support to the wound site, facilitating cell migration, proliferation, and tissue regeneration. Moreover, biological skin substitutes are widely used in the treatment of burns and chronic wounds, providing an effective alternative to traditional wound care methods. Their ability to address complex wounds makes them valuable in challenging clinical scenarios.

The topical agents segment is expected to grow significantly in the wound care biologics market during the forecast period. Topical agents in the wound care biologics market refer to therapeutic substances applied directly to the surface of wounds to facilitate healing and manage various aspects of the wound healing process. These agents can include a range of biologically derived substances designed to address specific aspects of wound care. The development and use of topical agents in wound care biologics continue to evolve, driven by advancements in biotechnology and regenerative medicine. These agents aim to provide targeted and effective solutions for promoting optimal wound healing outcomes.

End User Insights

The hospitals and clinics segment held the dominating share of the wound care biologics market. The segment is also observed to sustain dominance throughout the forecast period. Hospitals and clinics are primary settings for the assessment and diagnosis of wounds. Healthcare professionals in these settings evaluate the type and severity of wounds, determining the appropriate course of treatment, which may include the use of wound care biologics. In addition, healthcare providers in hospitals and clinics prescribe wound care biologics based on the patient's condition and the nature of the wound. They oversee the administration of these biologics, ensuring proper dosage and application. Thereby, driving the segment expansion.

Regional Insights

North America is expected to dominate the wound care biologics market during the forecast period. The region's increased number of burn injury cases and population of diabetics are the major causes of this. The increased occurrence of various lifestyle conditions that result in chronic wounds, such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers, is also anticipated to be a major driver of the advanced wound care management market's expansion in the upcoming years. In May 2021, Mission Regional Medical Center reported that about 2 million Americans with diabetes each year will get a diabetic foot ulcer or similar non-healing sore. In the United States, there are already over 29 million people with diabetes.

Moreover, 37.3 million Americans, or 1 in 10 of the population, have diabetes, according to Centers for Disease Control and Prevention Updates from January 2022. 96 million adult Americans, or more than one in three, have prediabetes. Therefore, it is expected that the growing prevalence of diabetes foot in the United States and the rising incidence of diabetes, which is a key risk factor for the formation of foot ulcers, would drive demand for wound care biologics and accelerate market expansion throughout the projection period.

Asia Pacific is expected to witness the fastest growth rate in the wound care biologics market during the forecast period. Rapid economic growth and rising disposable incomes in countries such as China, India, and Southeast Asian nations are leading to increased healthcare spending. As a result, patients are more willing and able to invest in advanced wound care treatments, driving market growth. There is an increasing awareness among healthcare professionals and patients about the importance of advanced wound care products, including biologics, in promoting wound healing and preventing complications. This heightened awareness is driving the adoption of wound care biologics in the region.

Recent Developments

• In May 2022, the Department of Defense provided USD 4.6 million to MIMEDX for the evaluation of PURION processed Dehydrated Human Amnion Chorion Membrane (DHACM) to improve the treatment of burns and wounds sustained in combat casualties.
• In February 2023, the first-ever compact, flexible, elastic bandage that delivers electrotherapy directly to the wound site to speed up healing was created by Northwestern University researchers.
• In January 2023, Convatec announced the introduction of ConvaFoamTM in the United States. This sophisticated foam dressing family is intended to meet the demands of both patients and healthcare practitioners. ConvaFoamTM is the easy dressing option for wound care and skin protection since it can be applied to a variety of wound types at any point in the wound journey.

Wound Care Biologics Market Companies

• Stryker Corporation
• MIMEDX Group, Inc.
• Lavior Pharma Inc.
• Skye Biologics Holdings, LLC
• Integra LifeSciences Holdings Corporation
• ORGANOGENESIS HOLDINGS INC.
• ConvaTec Group plc
• Tissue Regenix Group Plc
• Kerecis
• Smith & Nephew plc

Segments Covered in the Report

By Wound Type

• Chronic Wound
• Acute Wound

By Product

• Topical Agents
• Biological Skin Substitutes

By End User

• Hospitals and Clinics
• Wound Centers and Burn Centers
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa